A new report today by the Office of Health Economics (OHE) called for a shake up in the way future antibiotics are to be rewarded in Europe so that biopharmaceutical companies can spend more to fight superbugs.
Antimicrobial resistance (AMR) is becoming a major global public health threat. In this new OHE Research Paper, the authors identify barriers to the development of new products and recommend a hybrid push-pull approach to encouraging innovation.
Antimicrobial resistance to drugs is a growing global public health issue. The EU began a discussion in 2009 about which policies can best encourage the development of new antibiotics. New OHE research uses an economic model to indentify which incentives for innovation are likely to be most successful.